Effect of insulin analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1 and M2.
BACKGROUND: In diabetic patients, the pharmacokinetics of injected human insulin does not permit optimal control of glycemia. Fast and slow acting insulin analogues have been developed, but they may have adverse properties, such as increased mitogenic or anti-apoptotic signaling. Insulin/IGF1 hybrid...
Main Authors: | Cécile Pierre-Eugene, Patrick Pagesy, Tuyet Thu Nguyen, Marion Neuillé, Georg Tschank, Norbert Tennagels, Cornelia Hampe, Tarik Issad |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3406060?pdf=render |
Similar Items
-
In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites.
by: Mark R Sommerfeld, et al.
Published: (2010-01-01) -
Insulin glargine affects the expression of Igf-1r, Insr, and Igf-1 genes in colon and liver of diabetic rats
by: Clara I Juárez-Vázquez, et al.
Published: (2018-05-01) -
Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine
by: E Warren, et al.
Published: (2004-11-01) -
Molecular Modeling and Bioinformatics Analysis of Drug-Receptor Interactions in the System Formed by Glargine, Its Metabolite M1, the Insulin Receptor, and the IGF1 Receptor
by: Margarita González-Beltrán, et al.
Published: (2021-09-01) -
On the safety of insulin Glargine
by: Ivan Ivanovich Dedov, et al.
Published: (2009-09-01)